Volume‐targeted showed no clear difference in air leak (any) compared with pressure‐limited ventilation: additional findings (low certainty).
Volume‐targeted showed no clear difference in pulmonary interstitial emphysema compared with pressure‐limited ventilation: additional findings (low certainty).
Volume‐targeted probably leads to lower death or BPD (36 weeks) compared with pressure‐limited ventilation: main findings (moderate certainty).
Volume‐targeted showed no clear difference in any IVH compared with pressure‐limited ventilation: additional findings (low certainty).
Volume‐targeted probably leads to lower PVL compared with pressure‐limited ventilation: additional findings (moderate certainty).
Volume‐targeted showed no clear difference in any IVH or PVL compared with pressure‐limited ventilation: additional findings (moderate certainty).
Volume‐targeted showed no clear difference in BPD (supplemental oxygen at 28 days) compared with pressure‐limited ventilation: additional findings (low certainty).
Volume‐targeted probably leads to lower pneumothorax compared with pressure‐limited ventilation: main findings (moderate certainty).
Volume‐targeted probably leads to lower IVH grade 3‐4 compared with pressure‐limited ventilation: main findings (moderate certainty).
Volume‐targeted probably leads to lower IVH grade 3‐4 or PVL compared with pressure‐limited ventilation: main findings (moderate certainty).
Volume‐targeted may leads to lower BPD (supplemental oxygen at 36 weeks) compared with pressure‐limited ventilation: main findings (low certainty).
Volume‐targeted showed no clear difference in death or BPD (28 days) compared with pressure‐limited ventilation: additional findings (low certainty).
Volume‐targeted showed no clear difference in failure of mode of ventilation compared with pressure‐limited ventilation: additional findings (moderate certainty).
Arginine probably leads to lower NEC any stage Bell's criteria compared with placebo (moderate certainty).
Arginine probably leads to lower stage 1 NEC Bell's criteria compared with placebo (moderate certainty).
Arginine showed no clear difference in stage 2 NEC Bell's criteria compared with placebo (moderate certainty).
Arginine showed no clear difference in stage 3 NEC Bell's criteria compared with placebo (moderate certainty).
Arginine showed no clear difference in mortality due to any cause compared with placebo (low certainty).
Arginine showed no clear difference in side effects ‐ hypotension compared with placebo (moderate certainty).